Today: 8 February 2026
Subscribe
Browse Category

Healthcare News News 9 August 2025 - 29 November 2025

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1 Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. Simply Wall St+1 Today’s news flow (November 29, 2025) gives investors plenty to chew on: Below is a
29 November 2025
···
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now. 1. Medicare’s New Drug Prices Hit GSK’s Trelegy and Breo Ellipta The biggest GSK headline today comes from Washington: Medicare has released the second round of negotiated prices for 15 of its costliest prescription medicines, with two GSK respiratory products on the list. Newsweek+3Reuters+3pharmaphorum+3 Key details: These new prices are scheduled to
26 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and telehealth partners. The changes come just days after the Trump administration struck landmark pricing agreements with Novo Nordisk and Eli Lilly that will extend Medicare and Medicaid coverage to obesity drugs for the first time and launch a government-run discount pharmacy site, TrumpRx, in early 2026. The White House+2Reuters+2 At the same time, telehealth and discount platforms including GoodRx and
17 November 2025
·
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States.GlobeNewswire+1 TONMYA Officially Launches in the U.S. Tonix announced at 7:00 a.m. EST that TONMYA is available for pharmacy ordering nationwide and can now be prescribed for adults with fibromyalgia.GlobeNewswire The drug is: TONMYA became the first new FDA‑approved therapy for fibromyalgia in more than 15 years when regulators cleared it on August 15, 2025, based on two pivotal Phase 3 trials involving nearly 1,000 patients.Tonix
17 November 2025
·
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire+1 JAZZ stock today: volatility after a major cancer win As of early afternoon U.S. trading on Monday, November 17, Jazz Pharmaceuticals shares are trading around $141.07, little changed on the day according to real‑time quote data. Earlier, however, markets reacted far
17 November 2025
·
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal adenocarcinoma, a group that includes cancers of the stomach, gastroesophageal junction, and esophagus. GlobeNewswire+1 The trial compared three regimens: According to Zymeworks and its partners Jazz Pharmaceuticals and BeOne Medicines, HERIZON‑GEA‑01 delivered several key findings: GlobeNewswire+2GlobeNewswire+2 On the back of these data, Jazz plans to: GlobeNewswire+1 For Zymeworks, which originally discovered Ziihera using its Azymetric™ bispecific antibody platform, the company
17 November 2025
··
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

What happened today Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) announced that it has successfully achieved target loading concentrations for two topical rapamycin delivery technologies—4% in its lotion and 5% in a dermal patch. The company said it will start manufacturing clinical and stability batches this quarter and is planning clinical testing in the first half of 2026. Initial targets include MLM and VM, which currently lack any FDA‑approved treatments. GlobeNewswire Quoin’s topical rapamycin program is identified on its pipeline page as QRX009, a formulation designed to improve skin penetration and local delivery—an area the company says has limited the performance of
11 November 2025
··
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings Inc. (NASDAQ: ENGN) reported fresh preliminary data this morning from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid (formerly EG‑70) in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS. The readout shows a 62% complete response (CR) at 6 months (n=37), 56% at 3 months (n=62) and 63% CR at any time (n=62) under the trial’s amended protocol—plus a favorable safety profile (42% treatment‑related adverse events; 1.6% dose interruptions; 0.8% discontinuations). The company completed enrollment of 125 patients in the pivotal cohort, above target, and will refine its analysis with FDA input on
11 November 2025
··
Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Company Overview – Innovating in Women’s Health Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick (a female inventor-entrepreneur), Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologiesfemasys.comgurufocus.com. The company’s mission is to provide women with minimally invasive, office-based alternatives that improve patient care and reduce costs, in areas ranging from infertility to contraception and cancer diagnosticsfemasys.comgurufocus.com. Safety and accessibility are emphasized – Femasys notes that advances in female reproductive health are “long overdue,” and its products are designed to be
3 November 2025
·
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com. Symphony’s first target analyte is interleukin-6 (IL-6), an inflammatory marker that rises during infection and sepsis. In hospitals today, diagnosing sepsis early
9 October 2025
··
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 (another +6.8%) investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive
2 October 2025
··
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Drug Approvals & Regulatory Developments (In Europe, regulators also made news: the EMA’s committee recommended approving darolutamide (Bayer’s Nubeqa) with hormone therapy for metastatic prostate cancer based on positive Phase 3 data onclive.com.) Clinical Trials & Research Breakthroughs Public Health & Policy Industry & Business Updates Sources: Key information and quotes in this report were drawn from Reuters news wires reuters.com reuters.com, official WHO releases who.int pharmabiz.com, and industry trade outlets including Fierce Biotech/Pharma fiercepharma.com fiercepharma.com and company statements. Each development is linked to its original source for further reading.
9 August 2025
·
1 2

Stock Market Today

Lynas Rare Earths share price slides after ASX selloff — what to watch before Monday

Lynas Rare Earths share price slides after ASX selloff — what to watch before Monday

8 February 2026
Lynas Rare Earths closed Friday down 3.2% at A$14.27, extending losses after a 7.9% drop Thursday. The S&P/ASX 200 fell 2.0% to 8,708.80, pressuring miners. No new disclosures since Lynas’ January update, when it reported a 43% rise in quarterly sales revenue despite power outages. CEO Amanda Lacaze will retire at the end of the financial year.
ANZ share price: What to watch after Friday’s slide into next week

ANZ share price: What to watch after Friday’s slide into next week

8 February 2026
ANZ shares closed down 1.5% at A$37.01 on Friday as director Graham Hodges prepares to step down Sunday. The stock remains up nearly 20% over the past year. Investors await key updates from major Australian banks next week, with ANZ’s first-quarter trading update set for Feb. 12. The ASX 200 fell 2% Friday amid broader market jitters.
Go toTop